Skip to main content
SpringerLink
Log in

Renin–angiotensin–aldosterone system blockade in chronic kidney disease: current strategies and a look ahead

  • IM - REVIEW
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

The Renin–Angiotensin–Aldosterone System (RAAS) is profoundly involved in the pathogenesis of renal and cardiovascular organ damage, and has been the preferred therapeutic target for renal protection for over 30 years. Monotherapy with either an Angiotensin Converting Enzime Inhibitor (ACE-I) or an Angiotensin Receptor Blocker (ARB), together with optimal blood pressure control, remains the mainstay treatment for retarding the progression toward end-stage renal disease. Combining ACE-Is and ARBs, or either one with an Aldosterone Receptor Antagonist (ARA), has been shown to provide greater albuminuria reduction, and to possibly improve renal outcome, but at an increased risk of potentially severe side effects. Moreover, combination therapy has failed to provide additional cardiovascular protection, and large prospective trials on hard renal endpoints are lacking. Therefore this treatment should, at present, be limited to selected patients with residual proteinuria and high renal risk. Future studies with novel agents, which directly act on the RAAS at multiple levels or have a more favourable side effect profile, are greatly needed to further explore and define the potential for and the limitations of profound pharmacologic RAAS inhibition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED Jr (1972) Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 52:633–652

    Article  CAS  PubMed  Google Scholar 

  2. Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovich RA (1974) An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med 17(291):817–821

    Article  Google Scholar 

  3. Remuzzi G, Ruggenenti P (2002) Perico. Chronic renal diseases: renoprotective benefits of renin–angiotensin system inhibition. N. Ann Intern Med 16(136):604–615

    Article  Google Scholar 

  4. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005) Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 10(366):2026–2033

    Article  Google Scholar 

  5. USRDS Annual Data Report (2015) http://www.usrds.org/adr.asp. Accessed 28 Jan 2016

  6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 11(329):1456–1462

    Article  Google Scholar 

  7. Locatelli F, Carbarns IR, Maschio G, Mann JF, Ponticelli C, Ritz E, Alberti D, Motolese M, Janin G, Zucchelli P, The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group (1997) Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. Kidney Int Suppl 63:S63–S66

    CAS  PubMed  Google Scholar 

  8. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 17(352):1252–1256

    Article  Google Scholar 

  9. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, African American Study of Kidney Disease and Hypertension Study Group (2006) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 20;288:2421-2431. Erratum in: JAMA. Jun 21;295(23):2726

  10. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 12(354):131–140

    Article  Google Scholar 

  11. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, AIPRD Study Group (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 19(139):244–252

    Article  Google Scholar 

  12. Ruggenenti P, Iliev I, Costa GM, Parvanova A, Perna A, Giuliano GA, Motterlini N, Ene-Iordache B (2008) Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial Study Group. Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). Diabetes Care 31:1629–1634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Leoncini G, Viazzi F, Pontremoli R (2012) RAAS inhibition and renal protection current pharmaceutical design. Curr Pharm Des 18:971–980

    Article  PubMed  Google Scholar 

  14. Brenner BM, Cooper ME, de Zeeuw D, for the RENAAL Study Investigation et al (2001) Effect of losartan on renal and cardiovascular outcome in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869

    Article  CAS  PubMed  Google Scholar 

  15. Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860

    Article  CAS  PubMed  Google Scholar 

  16. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961

    Article  CAS  PubMed  Google Scholar 

  17. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 10(358):1547–1559

    Google Scholar 

  18. Staessen JA, Li Y, Richart T (2006) Oral renin inhibitors. Lancet 368:1449–1456

    Article  CAS  PubMed  Google Scholar 

  19. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK (2008) AVOID Study Investigators Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 5(358):2433–2446

    Article  Google Scholar 

  20. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE Investigators (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2204–2213

    Article  CAS  PubMed  Google Scholar 

  21. Bianchi S, Batini V, Bigazzi R (2015) The renal effects of mineralocorticoid receptor antagonists. Int J Cardiol 1(200):20–24

    Article  Google Scholar 

  22. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Kennedy Cruickshank J, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, for The British Hypertension Society’s PATHWAY Studies Group (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386:2059–2068

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD (2009) Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20:2641–2650

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B (2006) Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1:940–951

    Article  CAS  PubMed  Google Scholar 

  25. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF (2009) Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 4:542–551

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM, Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 1(314):884–894

    Article  Google Scholar 

  27. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF (2014) Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 4:CD007004

    PubMed  Google Scholar 

  28. Epstein M (2006) Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 119:912–919

    Article  CAS  PubMed  Google Scholar 

  29. Atlas S (2007) The renin–angiotensin–aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 13:9–20

    PubMed  Google Scholar 

  30. Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin–angiotensin system on proteinuria in renal disease. Ann Intern Med 1(148):30–48

    Article  Google Scholar 

  31. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 16(372):547–553

    Article  Google Scholar 

  32. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P (2013) Guarino P; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 14(369):1892–1903

    Article  Google Scholar 

  33. Esteras R, Perez-Gomez MV, Rodriguez-Osorio L, Ortiz A, Fernandez-Fernandez B (2015) Combination use of medicines from two classes of renin–angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function. Ther Adv Drug Saf 6:166–176

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. European Regolatory Agency http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/02/news_detail_001446.jsp&mid=WC0b01ac058004d5c1 Accessed 25 Jan 2016

  35. Preston RA, Afshartous D, Garg D, Medrano S, Alonso AB, Rodriguez R (2009) Mechanisms of impaired potassium handling with dual renin–angiotensin–aldosterone blockade in chronic kidney disease. Hypertension 53:754–760

    Article  CAS  PubMed  Google Scholar 

  36. Van Buren PN, Adams-Huet B, Nguyen M, Molina C, Toto RD (2014) Potassium handling with dual renin–angiotensin system inhibition in diabetic nephropathy. Clin J Am Soc Nephrol 9:295–301

    Article  PubMed  PubMed Central  Google Scholar 

  37. Rales Investigators (1996) Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 15(78):902–907

    Google Scholar 

  38. Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J (2006) Dual blockade of the renin–angiotensin system in the progression of renal disease: the need for more clinical trials. J Am Soc Nephrol 17:S250–S254

    Article  PubMed  Google Scholar 

  39. Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL (2013) Efficacy and safety of combined vs. single renin–angiotensin–aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens 26:424–441

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G (2008) Antiproteinuric response to dual blockade of the renin–angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 52:475–485

    Article  PubMed  Google Scholar 

  41. Cheng J, Zhang X, Tian J, Li Q, Chen J (2012) Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. Int J Clin Pract 66:917–923

    Article  CAS  PubMed  Google Scholar 

  42. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J (2007) Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 24:486–493

    Article  CAS  PubMed  Google Scholar 

  43. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD (2006) Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 48:8–20

    Article  CAS  PubMed  Google Scholar 

  44. de Zeeuw D (2013) The end of dual therapy with renin–angiotensin–aldosterone system blockade? N Engl J Med 14(369):1960–1962

    Article  Google Scholar 

  45. Hunsicker LG, Atkins RC, Lewis JB, Braden G, de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ Collaborative Study Group (2004) Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl 92:S99–S101

    Article  CAS  PubMed  Google Scholar 

  46. Gentile G, Remuzzi G, Ruggenenti P (2015) Dual renin–angiotensin system blockade for nephroprotection: still under scrutiny. Nephron 129:39–41

    Article  CAS  PubMed  Google Scholar 

  47. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Perna A, Remuzzi G (2008) Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 19:1213–1224

    Article  PubMed  PubMed Central  Google Scholar 

  48. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA et al (2015) Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 14(314):151–161

    Article  Google Scholar 

  49. Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B (2015) Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 15(372):222–231

    Article  Google Scholar 

  50. Mario Negri Institute for Pharmacological Research, Agenzia Italiana del Farmaco. Preventing Microalbuminuria in Type 2 Diabetes (VARIETY). ClinicalTrials.gov Identifier: NCT00503152 Available: https://clinicaltrials.gov/ct2/show/NCT00503152?term=VARIETY+NCT00503152&rank=1 Accessed 28 Jan 2016

  51. Mario Negri Institute for Pharmacological Research, Agenzia Italiana del Farmaco. Preventing ESRD in Overt Nephropathy of Type 2 Diabetes (VALID). ClinicalTrials.gov Identifier: NCT00494715 Available: https://clinicaltrials.gov/ct2/show/NCT00494715?term=VALID%2C+NCT00494715&rank=1 Accessed 28 Jan 2016

  52. Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S, SMART (Supra Maximal Atacand Renal Trial) Investigators (2009) Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 20:893–900

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Hollenberg Norman K, Parving Hans-Henrik, Viberti Giancarlo, Remuzzi Giuseppe, Ritter Susan, Zelenkofske Steven, Kandra Albert, Daleye William L, Rocha Ricardo (2007) Renal disease albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 25:1921–1926

    Article  CAS  PubMed  Google Scholar 

  54. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients Type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 6(376):1543–1551

    Article  Google Scholar 

  55. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL (2011) Addition of atrasentan to renin–angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22:763–772

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K (2015) Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J 7(36):1967–1973

    Article  Google Scholar 

  57. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ (2000) Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 19(356):615–620. Erratum in: Lancet 2000 18(356):1774

  58. Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, Wojciechowski D, Ansmite B, Skards J, Laks T, Henry D, Packer M, Pfeffer MA (2005) OVERTURE Investigators. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Am Heart J 150:257–262

    Article  CAS  PubMed  Google Scholar 

  59. Braunwald E (2015) The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure. J Am Coll Cardiol 17(65):1029–1041

    Article  Google Scholar 

  60. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004

    Article  PubMed  Google Scholar 

  61. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ (2012) Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380:1387–1395

    Article  CAS  PubMed  Google Scholar 

  62. http://www.harp3trial.org/ Accessed 29 Jan 2016

Download references

Author information

Authors and Affiliations

  1. Università degli Studi and IRCCS A.O.U. San Martino-IST, Largo Rosanna Benzi 10, 16132, Genoa, Italy

    Francesca Viazzi, Barbara Bonino, Francesca Cappadona & Roberto Pontremoli

Authors
  1. Francesca Viazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Bonino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesca Cappadona
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberto Pontremoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Pontremoli.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Viazzi, F., Bonino, B., Cappadona, F. et al. Renin–angiotensin–aldosterone system blockade in chronic kidney disease: current strategies and a look ahead. Intern Emerg Med 11, 627–635 (2016). https://doi.org/10.1007/s11739-016-1435-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-016-1435-5

Keywords

Search

Navigation